caa a22 4500 605490260 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0696-0 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0696-0 Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy [Elektronische Daten] [Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa] Abstract : Background: Patients with advanced local-stage, high-grade prostate cancer (Pca) and high pretreatment prostate-specific antigen (PSA) levels have inferior outcomes compared to their counterparts with more favorable clinical characteristics. However, some patients exhibit favorable pathological features or experience long-term PSA-free survival after radical prostatectomy (RP). We retrospectively examined the ability of preoperative characteristics to predict pathological and oncological outcomes in high-risk Pca patients who underwent RP. Methods: We examined data of 1,268 consecutive Pca patients treated with RP alone at 4 hospitals from the Michinoku Urological Cancer Study Group database. Preoperative predictors included age, PSA level, biopsy Gleason score, clinical T stage, and PSA density (PSAD). The outcome measures pathological T stage and PSA-free survival were evaluated by multivariate analysis. Results: We identified 380 high-risk Pca patients, of which 44% patients had extracapsular extension. Logistic regression analysis indicated that PSAD was an independent predictor of adverse pathologic stage. The 5-year PSA-free survival rates were 82.9% for patients with PSAD≤0.468ngmL−1cm−2 and 50.7% for those with PSAD>0.468ngmL−1cm−2 (P<0.0001). Multivariate analyses revealed that PSAD, cT, and the number of preoperative high-risk Pca criteria were independent predictors of PSA-free survival. Conclusions: PSAD may be an independent predictor of advanced pathological features and biochemical recurrence in high-risk Pca patients treated with RP alone. PSAD may be used for further risk stratification of high-risk Pca patients. Japan Society of Clinical Oncology, 2014 Prostate cancer nationallicence High-risk nationallicence Prostate-specific antigen density nationallicence Advanced prostate cancer nationallicence Biochemical recurrence-free survival nationallicence Koie Takuya Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Mitsuzuka Koji Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Yoneyama Takahiro Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Narita Shintaro Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Kawamura Sadafumi Department of Urology, Miyagi Cancer Center, Natori, Japan aut Kaiho Yasuhiro Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Tsuchiya Norihiko Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Tochigi Tatsuo Department of Urology, Miyagi Cancer Center, Natori, Japan aut Habuchi Tomonori Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut Arai Yoichi Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut Ohyama Chikara Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Yoneyama Tohru Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut Tobisawa Yuki Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 176-181 1341-9625 20:1<176 2015 20 10147 https://doi.org/10.1007/s10147-014-0696-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0696-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Koie Takuya Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Mitsuzuka Koji Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Yoneyama Takahiro Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Narita Shintaro Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Kawamura Sadafumi Department of Urology, Miyagi Cancer Center, Natori, Japan aut NATIONALLICENCE 700 1- Kaiho Yasuhiro Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Tsuchiya Norihiko Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Tochigi Tatsuo Department of Urology, Miyagi Cancer Center, Natori, Japan aut NATIONALLICENCE 700 1- Habuchi Tomonori Department of Urology, Akita University Graduate School of Medicine, Akita, Japan aut NATIONALLICENCE 700 1- Arai Yoichi Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan aut NATIONALLICENCE 700 1- Ohyama Chikara Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Yoneyama Tohru Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 700 1- Tobisawa Yuki Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 176-181 1341-9625 20:1<176 2015 20 10147